Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.
Also called NCT01309828
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 153 participants
- Sponsor
- Registry
-
NCT01309828 -
2010-023098-21 -
U1111-1119-5131
-
- Other papers using this trial's data
- Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bulgaria, Germany, Latvia, Lithuania, Netherlands, Poland, Slovakia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01309828. Randomized; no masking; primary purpose treatment. Start 2011-03 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2013-12-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease
- Condition
- Safety
- Intervention (Drug)
- Azilsartan medoxomil and chlorthalidone
- Intervention (Drug)
- Olmesartan medoxomil and hydrochlorothiazide
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01309828- Content hash
05eec0e1f7ca1167131157a1acdf66e47603a976db6979e4b6503acc7aa8573d